SGLT2i treatment during AKI and its association with major adverse kidney events

• Main Authors: Luz Alcantar-Vallin (Author), Jose J. Zaragoza (Author), Bladimir Díaz-Villavicencio (Author), Karla Hernandez-Morales (Author), Jahir R. Camacho-Guerrero (Author), Miguel A. Perez-Venegas (Author), Edgar J. Carmona-Morales (Author), Alexa N. Oseguera-Gonzalez (Author), Cesar Murguia-Soto (Author), Gael Chávez-Alonso (Author), José M. Arredondo-Dubois (Author), Carlos E. Orozco-Chan (Author), Juan A. Gómez-Fregoso (Author), Francisco G. Rodríguez-García (Author), Guillermo Navarro-Blackaller (Author), Ramón Medina-González (Author), Alejandro Martínez Gallardo-González (Author), Gabriela J. Abundis-Mora (Author), Olynka Vega-Vega (Author), Guillermo García-García (Author), Jonathan S. Chávez-Iñiguez (Author)
• Format: Book
• Published: Frontiers Media S.A., 2024-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

BackgroundThe association between the administration of sodium-glucose cotransporter 2 inhibitors (SGLT2is) during acute kidney injury (AKI) and the incidence of major adverse kidney events (MAKEs) is not known.MethodsThis retrospective cohort study included patients with AKI and compared the outcom...